Milestone Pharmaceuticals (NASDAQ:MIST – Get Free Report)‘s stock had its “buy” rating restated by research analysts at HC Wainwright in a report released on Friday,Benzinga reports. They presently have a $25.00 target price on the stock.
Milestone Pharmaceuticals Trading Down 6.3 %
NASDAQ MIST opened at $1.63 on Friday. The company has a quick ratio of 15.40, a current ratio of 15.40 and a debt-to-equity ratio of 2.18. Milestone Pharmaceuticals has a twelve month low of $1.12 and a twelve month high of $2.75. The firm has a market capitalization of $86.92 million, a PE ratio of -2.01 and a beta of 1.80. The stock’s 50 day moving average is $2.06 and its 200 day moving average is $1.76.
Institutional Investors Weigh In On Milestone Pharmaceuticals
Several hedge funds have recently made changes to their positions in the company. Toronto Dominion Bank bought a new stake in shares of Milestone Pharmaceuticals during the fourth quarter valued at approximately $1,770,000. Cubist Systematic Strategies LLC bought a new stake in Milestone Pharmaceuticals in the fourth quarter worth $73,000. Boxer Capital Management LLC bought a new stake in Milestone Pharmaceuticals in the fourth quarter worth $729,000. Northern Trust Corp boosted its holdings in Milestone Pharmaceuticals by 112.6% in the fourth quarter. Northern Trust Corp now owns 58,108 shares of the company’s stock worth $137,000 after acquiring an additional 30,772 shares in the last quarter. Finally, XTX Topco Ltd bought a new stake in Milestone Pharmaceuticals in the fourth quarter worth $80,000. 86.18% of the stock is currently owned by institutional investors.
Milestone Pharmaceuticals Company Profile
Milestone Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate.
See Also
- Five stocks we like better than Milestone Pharmaceuticals
- How to start investing in penny stocks
- Autodesk Designs Value for Investors: Uptrend Set to Continue
- Best Stocks Under $10.00
- Anheuser-Busch Stock Rallies—Is the King of Beers Back?
- 3 Natural Gas Stocks That Offer Great Dividend Yields
- MarketBeat Week in Review – 02/24 – 02/28
Receive News & Ratings for Milestone Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Milestone Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
